Menu
Amazon Kindle Voyage Rethinks the Reading Experience

Amazon Kindle Voyage Rethinks the Reading Experience

Mat Franco won America's Got Talent

Mat Franco won America's Got Talent

SpaceX and Boeing build manned NASA Spaceships

SpaceX and Boeing build manned NASA Spaceships

Matt Damon is Jason Bourne Again

Matt Damon is Jason Bourne Again

iPhone 6 Reviews are Glowing

iPhone 6 Reviews are Glowing

Diabetics Rejoice: MannKind's Insulin Inhaler Afrezza's FDA-Approved

Jun 29 2014, 5:22pm CDT | by , in News | Latest Business News

Being a Type 1 diabetic is expensive with limited medicine distribution methods and clunky carrying methods. MannKind's Afreeza is looking to change that.

Diabetics Rejoice: MannKind's Insulin Inhaler Afrezza's FDA-Approved
Photo Credit: Getty Images
 
 

YouTube Videos Comments

Full Story

Diabetics Rejoice: MannKind's Insulin Inhaler Afrezza's FDA-Approved

MannKind's inhaler insulin Afrezza gained F.D.A. approval, Friday, June 27. 

Andrew Pollack of the New York Times offers a lot of good news for insulin-dependent diabetics in "Afrezza, a New Inhaled Insulin, Is Approved by the F.D.A."

Fast-acting Afrezza is the size of a referee whistle, making it more convenient to carry around than traditionally bottled insulin or the pens. For diabetics having to carry insulin in order to survive, it'll be helpful. 



And unlike Pfizer's Exubera, there's a chance of success. Exubera was the size of a tennis ball, so transporting medication was impossible, and that’s vital for insulin-dependent patients.

As a Type 1 diabetic, I'm hoping Afrezza sticks around. This year was my 10th anniversary and I've gone from bottles to pens, noticing how nice it's been to carry my medication. I don’t qualify for an insulin pump, so right now these are my options.

Of course, price is always an issue. When I was using bottled Lantus in 2011, the price averaged about $120 per vial. And Humalog, my other medication, was $140. And that was without insurance. If you have to take several of each a month, it adds up. 

Not to mention the exclusivity of design means MannKind can determine market price. Many diabetics will see the importance and relevance, so more people will be interested in test-running the medication. That means cash-in-hand as the nation jumps on board to President Obama’s Affordable Healthcare Act.



There's also the cost of development and recouping the $2.3 billion already spent. And Mann himself has put in $900 million of his own money "but his roughly 40 percent stake in the company is worth around $1.6 billion.”

Alfred E. Mann, MannKind's chief executive, has personally invested that money in order to produce a viable delivery method. 

The 88-year-old billionaire seemed very content at the news. "Today’s F.D.A. action validates the years of clinical research and commitment that powered the development of this unique therapy." And Mann has experience in the diabetic field after creating MiniMed, an insulin pump business, which sold to Medtronic for $3 billion dollars. 

However, the F.D.A. did insist on more tests due to safety concerns by doctors. If a patient has any sort of breathing hindrance like asthma, COPD, or recently smoked, Afrezza won’t help them.



Questionable use involves Afrezza’s mealtime injection replacement for Type 1 diabetics, who are insulin-dependent and have limited options of delivery and medication. However, reports demonstrated “Afrezza provided less reduction in blood sugar than injected insulin, but the results were close enough that trial was deemed a success.”



Without a huge corporate backer, MannKind faces distribution struggles, according to Chief Financial Officer Matthew J. Pfeffer.  Pollack notes the CFO added “that Afrezza would not be available to patients until a partner was ready.”

Right now, the U.S. pharmaceutical corporations are buying each other out, or attempting to merge into a much stronger, but more homogenous business market.

In the United States, insulin is big business because it's harder to buy generic medication. Yet in Europe, generic insulin is gaining ground. Recently Eli Lilly, Humalog maker, won a European case for creating a generic version of Lantus when the patent runs out May 2015.



While it took two times to okay MannKind’s Afrezza, availability seems a lot closer at hand. 

Hopefully, the medicine will be on the market soon since the9.1% of the U.S. population are diabetics—that’s 29.1 million known patients. And the numbers only climb year-to-year. More options are better for patients.

 

 

Source: New York Times, MannKind Corporation, Irish Times, American Diabetes Association

 

You Might Also Like

Updates


Sponsored Update


Advertisement


More From the Web

Shopping Deals

 
 
 
 

Comments

blog comments powered by Disqus

Latest stories

Transport Tycoon Game Review
Transport Tycoon Game Review
Transport Tycoon is a realistic simulation game which seeks the attention of the users in building the whole new transport empire of one’s own. The game is filled with amazing and eye catching designs and features which keep you entertained throughout the whole time.
 
 
Amazon Introduces the Kindle Voyage
Amazon Introduces the Kindle Voyage
New Kindle Voyage is Amazon's thinnest, most advanced Kindle ever
 
 
Alexis Bledel Meets with "Sisterhood" Cast Mates
Alexis Bledel Meets with "Sisterhood" Cast Mates
Alexis Bledel Hangs Out with Former Cast Mates
 
 
Scotland Independence Vote Results Due Friday Morning
Scotland Independence Vote Results Due Friday Morning
Scotland is voting today in a referendum on Scotland's independence. The result will not be known until early morning Friday.
 
 
 

About the Geek Mind

The “geek mind” is concerned with more than just the latest iPhone rumors, or which company will win the gaming console wars. I4U is concerned with more than just the latest photo shoot or other celebrity gossip.

The “geek mind” is concerned with life, in all its different forms and facets. The geek mind wants to know about societal and financial issues, both abroad and at home. If a Fortune 500 decides to raise their minimum wage, or any high priority news, the geek mind wants to know. The geek mind wants to know the top teams in the National Football League, or who’s likely to win the NBA Finals this coming year. The geek mind wants to know who the hottest new models are, or whether the newest blockbuster movie is worth seeing. The geek mind wants to know. The geek mind wants—needs—knowledge.

Read more about The Geek Mind.